Articles

12 Feb 2008 MorphoSys Receives CTA Approval to Initiate Phase 1 Clinical Study for MOR103 Program
12 Feb 2008 Thallion Agrees with FDA on a Path Forward for Shigamabs Development Program in the U.S.
11 Feb 2008 2008 is a decisive year for the validation of the asthma target interleukin-13
11 Feb 2008 FDA issues Special Protocol Assessment (SPA) for pivotal Phase III trial with CA9-SCAN
08 Feb 2008 Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
08 Feb 2008 Novel anti-CD20 monoclonal antibody ofatumumab demonstrates anti-tumour responses in patients with relapsed/refractory B-cell chronic lymphocytic leukaemia
07 Feb 2008 Human Genome Sciences and Xencor Announce Genoma Collaboration
07 Feb 2008 InNexus Biotechnology Announces Preliminary Results of Animal Study Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment for Non-Hodgkin’s Lymphoma With Leading Marketed Product
07 Feb 2008 Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody
06 Feb 2008 FDA Agrees to Review Cimzia® File for the Treatment of Rheumatoid Arthritis
06 Feb 2008 OctoPlus commences United States Phase IIa study with Locteron for the treatment of hepatitis C
05 Feb 2008 FDA Gives Green Light to Lpath's ASONEP(TM) IND Submittal
05 Feb 2008 MedImmune Submits Biologics License Application to FDA for Motavizumab
04 Feb 2008 Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
04 Feb 2008 Promising Phase 3 Data for Ustekinumab (Cnto 1275) in Long-Term Improvement of Chronic Plaque Psoriasis
02 Feb 2008 Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis
01 Feb 2008 New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate to Severe Plaque Psoriasis
01 Feb 2008 ImmunoGen, Inc. Earns Milestone with IND Filing for BIIB015
31 Jan 2008 Pooled Phase 3 Study of Nplate(TM) (Romiplostim) in Adult Patients with Chronic ITP Published in the Lancet
31 Jan 2008 TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
30 Jan 2008 Viventia Biotech To Explore Strategic Alternatives
29 Jan 2008 Abbott and Eisai Finalize License Agreement in Japan for Additional Indications for Adalimumab, The Only Fully Human Monoclonal anti-TNFalpha Antibody
28 Jan 2008 Avastin receives broad label extension in Europe for the treatment of patients with metastatic colorectal cancer
28 Jan 2008 Abbott and Eisai Announce Changes in the Sales Scheme in Japan for Adalimumab, A Fully Human Monoclonal Anti-TNF-alpha Antibody
28 Jan 2008 Lpath Successfully Humanizes Breakthrough Anti-LPA Antibody, Lpathomab(TM)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top